CETUXIMAB WEEKLY (Q1W) VERSUS EVERY TWO WEEKS (Q2W) PLUS FOLFOX4 AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH KRAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC)

被引：0
|
作者：
Ciuleanu, Tudor [1 ]
Nikolic, Vladimir [2 ]
Shacham-Shmueli, Einat [3 ]
Vrbanec, Damir [4 ]
Plate, Signe [5 ]
Mrsic-Krmpotic, Zrinka [6 ]
Kahan, Zsuzsanna [7 ]
Purkalne, Gunta [8 ]
Brodowicz, Thomas [9 ]
Zielinski, Christoph [9 ]
机构：
[1] Inst Oncol, IL-69978 Cluj Napoca, Romania
[2] Inst Oncol & Radiotherapy, Belgrade, Serbia
[3] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Oncol, Tel Aviv, Israel
[4] Univ Zagreb, Univ Hosp Zagreb Rebro, HR-10002 Zagreb, Croatia
[5] Latvian Ctr Oncol, Riga, Latvia
[6] Univ Zagreb, Univ Hosp Tumors, HR-10002 Zagreb, Croatia
[7] Semmelweis Univ, Dep Diagnost Radiol & Oncotherapy, Budapest, Hungary
[8] P Stradins Univ Hosp, Riga, Latvia
[9] Med Univ Vienna, Div Clin Oncol, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：v22 / v22
页数：1
相关论文
共 50 条
  • [1] Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
    Ciuleanu, T.
    Nikolic, V.
    Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Krmpotic, Z. M.
    Dank, M.
    Purkalne, G.
    Brodowicz, T.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [2] Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Ciuleanu, T.
    Nikolic, V.
    Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Krmpotic, Z. M.
    Dank, M.
    Purkaine, G.
    Brodowicz, T.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Brodowicz, Thomas
    Vrbanec, Damir
    Kaczirek, Klaus
    Ciuleanu, Tudor-Eliade
    Knittelfelder, Regina
    Lindner, Elisabeth
    Messinger, Diethelm
    Zielinski, Christoph
    Streubel, Berthold
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [4] Optimal dose of cetuximab (C) given every 2 weeks (q2w):: A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC).
    Tabernero, J.
    Cervantes, A.
    Martinelli, E.
    Vega-Villegas, E.
    Rojo, F.
    Pérez-Fidalgo, A.
    Casado, E.
    Ciardiello, F.
    Zubel, A.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 142S - 142S
  • [5] Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab plus first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
    Price, Timothy Jay
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wen-Feng
    Gibbs, Peter
    Lim, Robert S. C.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules
    Ciardiello, F.
    Cervantes, A.
    Vega-Villegas, M.
    Casado, E.
    Rodriguez-Braun, E.
    Martinelli, E.
    Rojo, F.
    Baselga, J.
    Kisker, O.
    Tabernero, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 247 - 247
  • [7] Cetuximab given every 2 weeks (q2w) plus irinotecan, as feasible option, for previously treated patients (pts) with metastatic colorectal cancer (MCRC)
    Roca, J.
    Alonso, V.
    Pericay, C.
    Escudero, P.
    Grande, C.
    Vicente, P.
    Arrivi, A.
    Martin, C.
    Moreno, I.
    Garcia, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab plus first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.
    Price, Timothy Jay
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wen-Feng
    Gibbs, Peter
    Lim, Robert S. C.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [9] Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) - Primary endpoint and subgroup analysis of the CEBIFOX trial
    Kasper, S.
    Meiler, J.
    Knipp, H.
    Hoehler, T.
    Reimer, P.
    Steinmetz, H. T.
    Berger, W.
    Linden, G.
    Ting, S.
    Markus, P.
    Paul, A.
    Dechene, A.
    Schumacher, B.
    Kostbade, K.
    Worm, K.
    Schmid, K. W.
    Herold, T.
    Schuler, M.
    Trarbach, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
    Brodowicz, T.
    Ciuleanu, T. E.
    Radosavljevic, D.
    Shacham-Shmueli, E.
    Vrbanec, D.
    Plate, S.
    Mrsic-Krmpotic, Z.
    Dank, M.
    Purkalne, G.
    Messinger, D.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1769 - 1777
12345